Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by University of California, San Francisco
Susan G. Komen Breast Cancer Foundation
Information provided by (Responsible Party):
Hope Rugo, MD, University of California, San Francisco Identifier:
First received: May 7, 2012
Last updated: May 6, 2016
Last verified: May 2016
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.

Condition Intervention Phase
Metastatic Breast Cancer
Drug: PLX3397
Drug: Eribulin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Maximum tolerated dose of PLX3397 given in combination with with standard dose eribulin in patients with metastatic breast cancer (Phase 1b) [ Time Frame: Estimated up to 24 months ]
  • Percentage of patients with chemotherapy pre-treated triple negative metastatic breast cancer treated with PLX3397 in combination with eribulin who are progression free at 12 weeks (Phase 2) [ Time Frame: Evaluated at week 12 tumor assessment ]

Secondary Outcome Measures:
  • Serum concentrations for the combination of PLX3397 and eribulin (Phase 1b) [ Time Frame: Up to 42 days. ]
  • Safety of treatment (Phase 1b & 2) [ Time Frame: Approximately 24 months ]
    AE and toxicity assessments (laboratory tests, physical exams & history) on Days 1 and Day 8 of each cycle during treatment

  • Immune response (Phase 1b & 2) [ Time Frame: Up to 42 days. ]
  • Efficacy of drug combination including response rate and duration of response (Phase 2) [ Time Frame: Participants will be assessed every 3 weeks and have CT scans every 6 weeks during treatment. Average participation is approximately 24 months. ]

Estimated Enrollment: 80
Study Start Date: July 2012
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eribulin in combination with PLX3397

Phase Ib:

21 day treatment cycle: PLX3397 100-200 mg gelcaps, po daily & Eribulin 1.4 mg/m2 IV day 1 and 8

  • Cohort 1: 600 mg/day
  • Cohort 2: 800 mg/day
  • Cohort 3: 1000 mg/day

Phase II:

Lead in period of 5-7 d with PLX3397 at MTD po qd (day -7/5 to day 0)

21 day cycles; Day 1:

  • Add eribulin 1.4 mg/m2 IV day 1 and 8
  • Continue PLX3397 at MTD po qd
Drug: PLX3397
Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
Drug: Eribulin
Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
Other Names:
  • Halaven
  • E7389

Detailed Description:

This is a nonrandomized, open label phase Ib/II study evaluating the safety and efficacy of eribulin in combination with PLX3397, a novel CSF1 inhibitor, in patients with metastatic breast cancer. The phase II portion of this trial will be limited to patients with triple negative disease.

The phase I portion of this trial is a dose escalation of PLX3397 to determine the maximum tolerated dose (MTD) of PLX3397 when given in combination with standard dose eribulin. Patients will be enrolled in cohorts of three, using the dose levels and plan outlined in the statistical section, with 6 patients enrolled at the MTD. All patients with accessible tumor will be required to have a tumor biopsy at study start before starting therapy. Pharmacokinetics of PLX3397 and eribulin, and blood levels of CSF1 will be obtained as outlined in section 14. To allow rapid accrual to phase Ib, and an earlier start to the phase II trial, patients will be enrolled in phase I with both hormone receptor positive and negative disease, and at any line of therapy assuming eligibility criteria are otherwise met.

Dose limiting toxicity (DLT) will be defined as any treatment-related toxicity meeting the criteria below and occurring within the first 21 days of combination therapy. Patients must receive at least 14 days of PLX3397 and 2 doses of eribulin during the first cycle in order to be considered evaluable for DLT (unless the missed doses are due to a DLT).

Patients in each cohort will be followed for at least 3 weeks (one full cycle) before opening accrual to the next dose level. If one patient in any cohort develops a DLT, an additional 3 patients will be enrolled at that level. If no additional toxicities occur in the six patients, then this particular dose would be used for the phase II trial, and the next higher dose would be considered the MTD. A minimum of 12 and maximum of 24 patients will be enrolled in the phase I study. The phase II trial will not open until the last patient in the phase I study has been followed for at least 3 weeks.

The phase II portion of this trial will evaluate PFS in patients with TNBC treated with PLX3397 and eribulin, using the dose of PLX3397 determined in the phase Ib study in a two-step design. Please see the statistical section for details regarding enrollment and statistical design. Treatment is preceded by a 5 to 7 day lead-in phase, in which patients will take PLX3397 alone daily. Patients with accessible tumor will undergo a core biopsy of tumor before the start of PLX3397 treatment, and then a fine needle aspiration or core biopsy will be performed on the day of or the day before the start of eribulin (day -1 to day 0).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed diagnosis of breast cancer with documented progressive disease.
  • Patients with stable brain metastases are eligible for this trial.
  • At least one prior chemotherapy regimen for metastatic breast cancer. Prior treatment must be discontinued at least 2 weeks before treatment start.
  • Concomitant therapy with bisphosphonates is allowed.
  • Stable dose coumadin anticoagulation is allowed, providing that anticoagulation can be safely held to an INR within normal range for the purpose of tumor biopsy. LMWH is the preferred method of anticoagulation.
  • PT/INR and PTT within institutional normal limits within two weeks before initial biopsy.
  • Measurable disease, as defined by RECIST guidelines or evaluable disease. Bone metastases must be evaluable.
  • Disease amenable to core biopsy. Patients with pulmonary metastases as their only site of disease may enroll on this trial and will not undergo biopsy.
  • For Phase I: patients with HER2 overexpressing disease must have been previously treated with trastuzumab. Patients with HER2 overexpressing disease are not eligible for the Phase II trial.
  • Age eighteen years or older.
  • ECOG performance status </= 2.
  • Life expectancy of >/= 12 weeks.
  • Patients with < grade 1 peripheral neuropathy are eligible for this trial.
  • Adequate bone marrow reserve: ANC >/= 1000, platelets >/= 100,000.
  • Adequate renal function: serum creatinine </= 1.5x upper limit of normal OR calculated creatinine clearance ≥ 50 ml/min.
  • Sodium, potassium, and chloride levels within institutional normal limits.
  • Adequate hepatic function: AST and ALT </= 2.5 x ULN, and total bilirubin </= 1.5x upper limit of normal. In patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be </= 5 times the ULN.
  • At baseline: EF ≥ 50%, no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point - patients may be eligible for study if the drug can be changed to another agent with less risk (such as changing from citalopram to an alternate antidepressant).
  • Able to take oral medications and maintain hydration.
  • Ability to give written informed consent and willingness to comply with the requirements of the protocol
  • Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drug

Specific inclusion criteria for Phase II

• Patients enrolling on the phase II portion of this trial must have ER, PR and HER2 negative disease defined as less than 10% staining for ER and PR, and HER2 not amplified by FISH, 0-1% by IHC, or 2+ by IHC and no evidence of amplification by FISH.

Exclusion Criteria:

  • Treatment with another chemotherapy or hormonal therapy within the past 2 weeks.
  • Treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks.
  • Concurrent treatment with radiotherapy.
  • Ongoing treatment with any other investigational therapy.
  • Prior treatment with eribulin
  • Severe, concurrent illness including congestive heart failure, significant cardiac disease and uncontrolled hypertension, that would likely prevent the patient from being able to comply with the study protocol.
  • Inadequate bone marrow, renal, or hepatic function as defined above, or an active coagulopathy that precludes tissue biopsy.
  • Pregnant or lactating women and women of child-bearing potential who are not using an effective method of birth control. Women of childbearing potential must undergo a serum pregnancy test within seven days of starting the study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01596751

Contact: Hope S. Rugo, MD 415-353-7428

United States, California
UCSF Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94115
Contact: Amy DeLuca    415-353-7288   
Contact: Ivy Wong    415-353-7873   
Principal Investigator: Hope S. Rugo, MD         
United States, North Carolina
Duke University Cancer Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Kimberly Blackwell, MD    919-668-1748   
Principal Investigator: Kimberly Blackwell, MD         
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Ingrid Mayer, MD    615-322-4967   
Principal Investigator: Ingrid Mayer, MD         
Sponsors and Collaborators
Hope Rugo, MD
Susan G. Komen Breast Cancer Foundation
Study Chair: Hope S. Rugo, MD University of California, San Francisco
  More Information

Responsible Party: Hope Rugo, MD, Clinical Professor, University of California, San Francisco Identifier: NCT01596751     History of Changes
Other Study ID Numbers: UCSF Protocol No. 12751
Study First Received: May 7, 2012
Last Updated: May 6, 2016

Keywords provided by University of California, San Francisco:

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on April 25, 2017